Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 420 | 649 | 818 | 830 | 764 | 743 | 773 | 773 |
| Operating profit | €m | 173 | 170 | ||||||
| Net profit | €m | 61 | 153 | 200 | 170 | 137 | 140 | 185 | 143 |
| EPS reported | € | 2.75 | 3.62 | ||||||
| Operating cashflow per share | € | 3.62 | 4.94 | ||||||
| Capex per share | € | 1.27 | 1.48 | ||||||
| FCF per share | € | 2.35 | 3.46 | ||||||
| Free cash flow | €m | 120 | 177 | ||||||
| Net debt | €m | 8.1 | -20.4 | ||||||
| Book value equity | €m | 664 | 701 | ||||||
| Book value per share | € | 12.99 | 13.70 | ||||||
| Number of shares | m | 51.15 | 51.15 | ||||||
| DPS (TTM paid) | € | 0.94 | 0.96 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 23.09 | 16.16 | ||||||
| P/B LTM | x | 4.89 | 4.19 | ||||||
| P/S LTM | x | 4.37 | 3.80 | ||||||
| P/FCF LTM | x | 27.03 | 16.61 | ||||||
| EV/EBITDA LTM | x | 16.07 | 10.95 | ||||||
| EV/Sales LTM | x | 4.40 | 3.77 | ||||||
| Earnings Yield LTM | % | 4.33% | 6.19% | ||||||
| FCF Yield | % | 3.70% | 6.02% | ||||||
| Quality | |||||||||
| ROE | % | 21.14% | 27.84% | ||||||
| ROIC | % | 16.52% | 15.22% | ||||||
| Operating margin | % | 23.29% | 21.97% | ||||||
| Gross margin | % | 60.75% | 64.02% | ||||||
| FCF/Sales | % | 16.16% | 22.87% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +3.00% | -6.70% | ||||||
| Sales Growth YoY | % | -2.65% | +3.21% | ||||||
| Net Income Growth YoY | % | +2.60% | +40.00% | ||||||
| FCF Growth | % | +57.99% | +144.95% | ||||||
| Operating Profit Growth | % | -3.57% | -2.41% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.47% | 1.64% | ||||||
| Dividend Growth | % | -15.28% | +2.60% | ||||||
| Payout Ratio | % | 34.01% | 25.83% | ||||||
| FCF/Debt | x | 0.99 | 1.64 | ||||||
| Net Debt/EBITDA | x | 0.12 | -0.07 | ||||||
| EBIT/Net interest | x | 60.84 | 39.74 | ||||||
| Net debt/market cap | % | 0.25% | -0.69% | ||||||
| Net debt/Equity | x | 0.01 | -0.03 | ||||||
| Gross debt/equity | x | 0.18 | 0.15 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
Based on consensus from external analysts. Not Kvantra's opinion.
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free